Johnson & Johnson is to buy Momenta Pharmaceuticals for $6.5 billion, adding potential inflammatory diseases blockbuster nipocalimab to the pipeline at its Janssen pharmaceuticals unit.

Liva chief executive Shahram Sharif (centre) with chief operating officer Martin Paarse (left) and Discover Momenta CEO Harry MacMillan (right). Digital health ...

Founded in 2016, Momenta has captured more than 60% of China's urban Navigation on Autopilot (NOA) market for third-party... Save my User ID and Password Some subscribers prefer to save their log ...